MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4 by Xue, Chengyuan et al.
MYCN promotes neuroblastoma
malignancy by establishing a regulatory
circuit with transcription factor AP4
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Xue, C., D. M. Yu, S. Gherardi, J. Koach, G. Milazzo, L. Gamble, B.
Liu, et al. 2016. “MYCN promotes neuroblastoma malignancy by
establishing a regulatory circuit with transcription factor AP4.”
Oncotarget 7 (34): 54937-54951. doi:10.18632/oncotarget.10709.
http://dx.doi.org/10.18632/oncotarget.10709.
Published Version doi:10.18632/oncotarget.10709
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:32072027
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Oncotarget54937www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 34
IntroductIon
The MYC family of proto-oncogenes play important 
roles as transcriptional regulators in vital cellular functions 
[1]. The most well-characterised member of the family, 
MYC, is frequently deregulated in adult cancers [2, 3]. 
In neuroblastoma, the most common extracranial solid 
tumor of childhood accounting for approximately 15% 
of all childhood cancer related deaths, amplification 
of the MYCN oncogene in tumors represents one of the 
most powerful prognostic markers yet identified for 
this malignancy [4]. Although MYCN amplification and 
consequent overexpression has been established as a 
key driver of malignancy in MYCN-amplified high-risk 
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ABStrAct
Amplification of the MYCN oncogene, a member of the MYC family of transcriptional 
regulators, is one of the most powerful prognostic markers identified for poor 
outcome in neuroblastoma, the most common extracranial solid cancer in childhood. 
While MYCN has been established as a key driver of malignancy in neuroblastoma, 
the underlying molecular mechanisms are poorly understood. Transcription factor 
activating enhancer binding protein-4 (TFAP4) has been reported to be a direct 
transcriptional target of MYC. We show for the first time that high expression of 
TFAP4 in primary neuroblastoma patients is associated with poor clinical outcome. 
siRNA-mediated suppression of TFAP4 in MYCN-expressing neuroblastoma cells led 
to inhibition of cell proliferation and migration. Chromatin immunoprecipitation assay 
demonstrated that TFAP4 expression is positively regulated by MYCN. Microarray 
analysis identified genes regulated by both MYCN and TFAP4 in neuroblastoma cells, 
including Phosphoribosyl-pyrophosphate synthetase-2 (PRPS2) and Syndecan-1 
(SDC1), which are involved in cancer cell proliferation and metastasis. Overall this 
study suggests a regulatory circuit in which MYCN by elevating TFAP4 expression, 
cooperates with it to control a specific set of genes involved in tumor progression. 
These findings highlight the existence of a MYCN-TFAP4 axis in MYCN-driven 
neuroblastoma as well as identifying potential therapeutic targets for aggressive 
forms of this disease.
                   Research Paper
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neuroblastoma, the exact mechanisms by which MYCN 
contributes to the aggressive phenotype of neuroblastoma 
remain largely unknown [4]. Developing a greater 
understanding of some of the underlying mechanisms of 
MYCN-mediated neuroblastoma progression is important 
for identifying genes responsible for tumor progression as 
well as potential molecular therapeutic targets. 
TFAP4 is a member of the basic helix-loop-helix 
transcription factors that recognize the E-box sequence 
CAGCTG in the promoters of target genes [5], and has 
been shown to be a direct transcription target of MYC [6]. 
Recently, there has been increasing evidence that TFAP4 
plays important roles in human cancer development and 
progression and in particular, it has been found to be a 
direct inducer of epithelial–mesenchymal transition (EMT) 
that contributes to metastatic processes in colorectal cancer 
[7]. In addition, elevated TFAP4 expression significantly 
correlates with tumor progression and poor prognosis in 
a number of malignancies, including colorectal cancer 
[7, 8], gastric cancer [9] and non-small cell lung cancer 
[10]. Conversely, down-regulation of this transcription 
factor blocks proliferation of human gastric cancer cells 
[9] and inhibits metastasis of colorectal cancer cells 
in mice [7]. Therefore as a MYC transcriptional target, 
TFAP4 may play a critical role in cancer cells in concert 
with deregulated MYC, by coordinating the expression 
of specific genes that are essential for tumor progression. 
In this study, the relevance of TFAP4 in the context of 
MYCN-driven neuroblastoma was investigated. 
reSultS
TFAP4 is directly regulated by MYcn
Since TFAP4 has been reported to be a direct 
transcriptional target of MYC in adult breast cancer 
cells [6], we investigated whether a similar relationship 
exists between TFAP4 and MYCN in neuroblastoma by 
performing expression analysis following knockdown 
of MYCN in MYCN-amplified neuroblastoma cell lines 
BE(2)-C, CHP-134 and IMR-32. We observed that TFAP4 
protein levels were markedly downregulated following 
MYCN depletion (Figure 1A, Supplementary Figure S1A). 
Similar results were demonstrated in MYCN-inducible 
SH-EP/TET21/N human neuroblastoma cells following 
tetracycline treatment (Figure 1B, Supplementary 
Figure S1B). Additionally, increased MYCN expression 
was found to correlate with increased TFAP4 protein and 
RNA expression in SH-EP/S1 cells stably overexpressing 
MYCN compared to SH-EP/EV controls (Figure 1C, 
Supplementary Figure S1B). 
To assess whether MYCN is a direct transcriptional 
regulator of TFAP4, quantitative chromatin 
immunoprecipitation (qChIP) assays were performed 
in BE(2)-C and SH-EP/TET21/N cells. MYC has been 
reported to bind to three of four canonical E-boxes 
(CACGTG) in the first intron of TFAP4 [6]. Using MYCN 
and Max antibodies, we confirmed that both MYCN and 
Max strongly bound to these E-box motifs (amp A+B), 
but not to a control region (amp C) located in intron 6 of 
TFAP4 (Figure 1D–1E). Interestingly, differences in the 
relative ChIP enrichments observed between BE(2)-C and 
SH-EP/TET21/N cells reflect the intrinsic level of MYCN 
expressed in these cells which is markedly higher in 
BE(2)-C than SH-EP/TET21/N, even when the latter are 
induced to express MYCN. The fact that MYCN binding 
is consistently observed in both cell lines for E-box A but 
only in BE(2)-C for E-box B may be explained by the 
variability of fragmented DNA size used for the ChIP 
assays. Nevertheless, these observations are consistent 
with the accepted notion that MYC activity is exerted 
nearby the transcription start site, and that maximal 
binding of MYC to promoters occurs at the transcription 
start site and fades with distal E-box elements. Specificity 
of the MYCN binding to the E-box motifs was supported 
by a striking reduction of MYCN binding to DNA 
when MYCN expression was repressed (Figure 1E). 
Collectively, these data indicate that TFAP4 is a direct 
transcriptional target of MYCN in neuroblastoma. 
tFAP4 promotes cell growth in neuroblastoma
We next investigated whether TFAP4 promotes 
cell growth in MYCN-amplified neuroblastoma. We 
observed that knockdown of TFAP4 in both MYCN-
amplified neuroblastoma BE(2)-C cells, and SH-EP/
S1 neuroblastoma cells (stably overexpressing MYCN) 
resulted in a marked decrease in colony forming ability 
of these cells (Figure 2A), and cell cycle arrest at G1 and 
S phases (Figure 2B, Supplementary Figure S1C), while 
BE(2)-C cells also demonstrated a decrease in the cell 
population at G2/M phase. We next investigated potential 
alterations in cyclin-dependent kinase inhibitor levels and 
a marked upregulation of p27Kip1 (Cdkn1b) was observed 
in both cell lines (Figure 2C). These results show that 
suppression of TFAP4 leads to an increase in cyclin-
dependent kinase inhibitor levels, which may contribute 
to the reduced growth phenotype of neuroblastoma cells. 
tFAP4 is required for cell migration in MYcn-
overexpressing neuroblastoma cells
In addition to a growth inhibitory phenotype, 
we observed that TFAP4 knockdown in BE(2)-C cells 
also led to reduced cell motility compared with control 
siRNA transfected cells, as measured by wound closure 
(Figure 3A) and transwell migration assays (Figure 3B). To 
confirm the role of TFAP4 in neuroblastoma cell migration, 
we next performed cell migration assays after transiently 
overexpressing TFAP4 in MYCN non-amplified cell lines 
(SH-SY5Y and SK-N-FI), which express relatively low 
levels of both MYCN and TFAP4. In both SH-SY5Y 
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and SK-N-FI, overexpression of TFAP4 demonstrated 
enhanced migratory ability compared to empty vector-
transfected controls (Figure 3C, Supplementary 
Figure S2A). To further evaluate the importance of 
TFAP4 in MYCN-driven neuroblastoma migration, SH-
SY5Y neuroblastoma cells were transiently transfected 
initially with a MYCN-overexpressing construct, followed 
24 hours later by TFAP4 or control siRNA. While an 
increase in migration compared to controls was observed 
with MYCN overexpression, TFAP4 depletion abrogated 
this effect, restoring migration to similar levels as control 
siRNA-treated cells (Figure 3D). Taken together, these 
data suggest that TFAP4 is required for the MYCN-driven 
neuroblastoma migration phenotype.
TFAP4 gene expression is associated with poor 
clinical outcome in primary neuroblastoma
To determine whether TFAP4 has prognostic 
significance in primary neuroblastoma, we analysed TFAP4 
gene expression and its association with clinical outcome 
in an expression array dataset from a prospectively accrued 
primary neuroblastoma cohort of 649 patients (Oberthuer 
cohort) [11]. TFAP4 expression was strongly associated 
with both poor event-free survival (EFS) and overall 
survival (OS) when samples were dichotomised using the 
upper decile as a cut point (Figure 4A). These results were 
validated in another cohort of 208 patient samples from 
Children’s Oncology Group (COG) using qPCR-based 
Figure 1: tFAP4 is regulated by MYcn in neuroblastoma cells. Suppression of MYCN resulted in down-regulation of TFAP4 
in BE(2)-C cells (A). TFAP4 expression levels paralleled MYCN expression in SH-EP/TET21/N cells (MYCN Tet-Off system, 24 hours) 
(B) and in neuroblastoma SH-EP/S1 cells constitutively expressing exogenous MYCN compared with SH-EP/EV controls (c). GAPDH 
or Actin served as protein loading controls on Western blot. Quantitative ChIP assays in BE(2)-C cells (d) and SH-EP/TET21/N cells 
expressing MYCN (E) or treated with tetracycline (TET) for 48 h (e) demonstrated that MYCN directly binds to two E-box sites (amp 
A and B) located in the first intron of the TFAP4 gene, but not the control region (amp C). Western blot confirmed repression of MYCN 
expression with tetracycline treatment (E, inset). Mean ± SE (n = 3). amp, amplicon; TSS, transcription start site. **P < 0.01. 
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methodology (Figure 4B). However, multivariate analysis, 
taking into account patient age, stage and MYCN status, 
showed that TFAP4 was not an independent prognostic 
marker (data not shown), suggesting its upregulation 
could be largely dependent on MYCN overexpression. 
Concordantly, TFAP4 gene expression levels were 
significantly higher in MYCN-amplified tumors by 
comparison with non-MYCN amplified tumors (Figure 4C) 
and positively correlated with MYCN expression in both 
datasets (Supplementary Figure S2B). 
Figure 2: Inhibition of neuroblastoma cell growth following knockdown of TFAP4. Knockdown of TFAP4 reduced colony 
forming ability in MYCN-amplified BE(2)-C and MYCN-overexpressing SH-EP/S1 cells (A). Cell cycle analysis showed strong G1/S arrest 
48  h after TFAP4 depletion (B). Western blots showed increased p27 in TFAP4-depleted BE(2)-C and SH-EP/S1 (c). *P < 0.05, **P < 0.01, 
n.s.- not statistically significant.
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Identification of genes regulated by MYCN 
through tFAP4
Both MYCN and TFAP4 are known to be involved 
in regulation of important cell biological processes such 
as proliferation and migration [7, 12]. Thus, in order to 
identify a subset of genes that may be responsible for 
mediating the effects of MYCN and TFAP4, we performed 
expression array analyses of differential gene expression 
in BE(2)-C 30 h post-transfection with either MYCN or 
TFAP4 siRNA (GEO repository accession no. GSE74626). 
This relatively early timepoint was selected for gene 
expression analysis to identify direct target genes of both 
MYCN and TFAP4. Using a two-fold cut-off, the results 
showed that MYCN depletion resulted in downregulation 
of 98 genes out of a total of 20066 genes (0.49%), 
and three of these genes (3.06%), PRPS2, SDC1 and 
SLC7A6, were also downregulated with TFAP4 depletion 
(Supplementary Figure S2C), indicating that these genes 
were positively regulated by both MYCN and TFAP4. 
MYCN depletion also resulted in upregulation of 127 genes 
(0.63%), with 12 of these genes (9.45%) also upregulated 
following TFAP4 depletion, indicating that these genes 
were negatively regulated by the two transcription factors. 
The number of genes identified using a two-fold cut-off 
following MYCN siRNA-mediated inhibition 30 h post-
transfection, was similar to that found in a previous study 
in neuroblastoma using this time point [13].  In addition, 
no genes were found to be both upregulated by MYCN 
depletion and downregulated by TFAP4 depletion, or vice 
versa (Supplementary Figure S2C), which meant that 
TFAP4 and MYCN did not regulate gene expression in 
opposing directions.  
To confirm differential expression of these genes 
(Table 1), qPCR was performed on MYCN- and TFAP4-
depleted BE(2)-C cells except for the uncharacterized gene 
LOC100499177 (due to unavailability of TaqMan® assay). 
Loss of MYCN correlated with decreased expression of 
TFAP4 as well as the three positively regulated genes 
PRPS2, SDC1 and SLC7A6, and increased expression of 
the negatively regulated genes CYLD (Cylindromatosis), 
MFSD6, FMR1, CSGALNACT2, DENND5B, SSU72, 
LCORL, FAM73A and C19orf12 at 48 h post-transfection 
(Table 1). Expression of OIP5-AS1 was slightly increased 
after MYCN depletion but not statistically significant, 
and expression of COPS8 was unchanged (Figure 5A). 
For TFAP4 depletion, the qPCR data for every single 
gene tested was consistent with the microarray findings 
(Figure 5B). Thus, 12 out of the 15 differentially regulated 
genes identified in the expression array analyses were 
verified by qPCR.
PRPS2 and SDC1 are directly regulated by 
MYcn and tFAP4
It has been demonstrated in the literature that both 
MYCN and TFAP4 are effective at both activation and 
repression of target genes [7, 14]. Although most of our 
identified candidate genes were repressed by MYCN and 
TFAP4 we decided to focus on the positively regulated 
table 1: Genes showing two-fold differential expression 30 hours after depletion of MYCN or 
TFAP4 by sirnA knockdown in Be(2)-c neuroblastoma cells
Gene symbol Function
Genes downregulated by MYCN & TFAP4 siRNA
 PRPS2 Synthesis of purines and pyrimidines
 SDC1 Cell proliferation, migration and cell-matrix interactions
 SLC7A6 Amino acid transport
Genes upregulated by MYCN and TFAP4 siRNA
 CYLD Deubiquitination, inhibition of NF-kappa-B and HDAC6
 MFSD6 Transmembrane transport of small solutes 
 FMR1 Translational repression
 CSGALNACT2 Elongation during chondroitin sulfate synthesis
 DENND5B Promotes the exchange of GDP to GTP
 SSU72 Dephosphorylation of  RNA polymerase II C-terminal domain
 LCORL Spermatogenesis, association with adult height
 FAM73A Uncharacterized, likely responsible for obesity 
 C19orf12 Uncharacterized, mutation found in neurodegeneration 
 OIP5-AS1 Antisense RNA to OIP5 gene
 COPS8 positive regulation of E3 ubiquitin ligases
  LOC100499177 (uncharacterized gene) Uncharacterized
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genes for essentially two reasons. Firstly, MYCN 
negative regulation of target genes is not well defined 
and occurs either through interaction with other accessory 
transcription factors or through secondary mechanisms, as 
we have described [15]. Secondly, and more importantly, 
our interest is directed towards the identification of genes 
whose inhibition makes them potentially valuable targets 
for development of new anticancer therapies. We therefore 
chose to first examine the roles of PRPS2 and SDC1 that 
have been associated with rapid tumor progression and 
Figure 3: tFAP4 is required for neuroblastoma cell migration. Suppression of TFAP4 in BE(2)-C decreased cell motility in 
wound closure assays (A) (Scale bar 100μm). TFAP4 suppression decreased transwell migration (B). Overexpression of TFAP4 in MYCN-
non-amplified SH-SY5Y cells increased migration (c). Transient overexpression of MYCN in SH-SY5Y cells increased migration, and 
depletion of TFAP4 abrogated this effect (d). Western blots demonstrated successful transfection of MYCN plasmid, TFAP4 plasmid or 
TFAP4 siRNA (C, D). Mean ± SE (n = 3). *P < 0.05, **P < 0.01.
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metastasis in certain types of human cancers other than 
neuroblastoma [16–18]. At the protein level, suppression 
of MYCN resulted in dramatic decreases in expression of 
SDC1 and PRPS2 in neuroblastoma BE(2)-C and SH-EP/
TET21/N cells (Figure 6A–6B).  Consistently, knockdown 
of TFAP4 by siRNA corresponded with decreased SDC1 
and PRPS2 expression (Figure 6C–6D).
Examination of the promoter regions of PRPS2 and 
SDC1 revealed a number of MYCN and TFAP4 binding 
sites in close vicinity to one another (Figure 6E), however 
no interaction between MYCN and TFAP4 was detected 
by co-immunoprecipitation (data not shown), suggesting 
that PRPS2 and SDC1 may be cooperatively regulated 
by both MYCN and TFAP4. Subsequent ChIP assays in 
BE(2)-C confirmed that both MYCN and TFAP4 bound to 
the promoters of PRPS2 and SDC1 in the vicinity of their 
respective E-box binding motifs (CACGTG for MYCN 
and CAGCTG for TFAP4), but not the control regions 
(Figure 6E). Luciferase reporter assays also showed that 
activity for both PRPS2 and SDC1 was significantly 
decreased with TFAP4 or MYCN depletion, and further 
decreased with their combined depletion (Figure 6F). 
Taken together, these data indicate that both PRPS2 and 
SDC1 are co-operatively regulated by both MYCN and 
TFAP4 in neuroblastoma cells. 
PrPS2 and Sdc1 are effectors of MYcn-
mediated neuroblastoma progression 
Knockdown of PRPS2 or SDC1 led to a marked 
decrease in colony forming ability of BE(2)-C cells 
(Figure 7A–7B). Since SDC1 has been reported to 
mediate tumor growth and migration [19], we further 
investigated its role in the migration of BE(2)-C cells. 
We observed that suppression of SDC1 significantly 
decreased transwell migration of these cells, while 
repression of PRPS2 showed no effect on migration 
(Figure 7C–7D). Finally, we analyzed PRPS2 and SDC1 
expression and their association with clinical outcome in 
the 649 neuroblastoma expression array dataset. Kaplan–
Meier survival analysis showed that high levels of either 
PRPS2 or SDC1 expression were strongly associated with 
poor EFS and OS (Supplementary Figure S3A–S3B), 
suggesting that both these genes may play important 
roles in MYCN-driven neuroblastoma cell proliferation 
and tumor progression. The prognostic significance 
of these two genes was also retained when the analysis 
was confined to the subset of MYCN-amplified tumours 
(Supplementary Figure S3C) further suggesting a 
contribution to the MYCN-driven malignant phenotype. In 
addition, in the same dataset, we found that high levels of 
expression of SLC7A6, another gene positively regulated 
by MYCN and TFAP4, were significantly associated with 
poor EFS and OS, but high levels of expression of CYLD, 
a gene repressed by MYCN and TFAP4, were associated 
with good EFS and OS (Supplementary Figure S4A–S4B). 
the role of tFAP4 in the regulation of eMt in 
neuroblastoma 
TFAP4 has been shown to be a mediator of 
epithelial–mesenchymal transition (EMT) in colorectal 
cancer [7]. To investigate the role of this transcription 
factor in inducing an EMT phenotype in MYCN-amplified 
neuroblastoma, we investigated a panel of eleven critical 
EMT-associated genes, including ACTN4, KRT8, MYH9, 
ROCK1, TCF3, VIM (Vimentin), ZEB1, TWIST (TWIST1), 
SNAIL (SNAI1), CDH1 (E-cadherin) and CDH2 
(N-cadherin). Initially, we referred to our gene expression 
profiling data on BE(2)-C cells 30 h after depletion of 
TFAP4 with two different siRNAs to explore whether there 
was a significant change of expression of these genes. We 
found only subtle differential expression of these genes, 
with no single gene’s expression change being greater than 
1.5-fold following siRNA-mediated TFAP4 knockdown. 
Following this, we performed transient overexpression 
of TFAP4 in two neuroblastoma cell lines, SH-SY5Y and 
SK-N-FI which have relatively low levels of endogenous 
TFAP4. Overexpression of TFAP4 was confirmed by 
Western blot (data not shown) and RNA expression of the 
EMT-associated genes was measured by qPCR at 24 and 
48 hours post transfection (Supplementary Figure S5). 
We found that CDH1 was significantly upregulated by 
overexpression of TFAP4 at 24 and 48 hours in both SH-
SY5Y and SK-N-FI cell lines. SNAIL was significantly 
upregulated at 24 h in SH-SY5Y cells but not in SK-N-
FI cells, although a trend of increasing expression was 
observed in SK-N-FI cells. KRT8 and ZEB1 expression 
were reduced at 24 h in response to elevated TFAP4 levels 
in SH-SY5Y cells. KRT8 expression was also lower at 
24 h in SK-N-FI cells but not statistically significant. The 
remaining genes displayed no significant change in the 
presence of overexpressed TFAP4. 
dIScuSSIon 
In this study, we have demonstrated that TFAP4 is 
a direct transcriptional target of MYCN in neuroblastoma 
and that high levels of this transcription factor are 
associated with poor clinical outcome in this disease. 
Furthermore, TFAP4 and MYCN co-operatively regulate 
a defined subset of genes to drive cell proliferation and 
migration in MYCN-driven neuroblastoma cells. 
The present study identified 15 genes with more than 
two-fold changes in gene expression profiling that appear 
to be regulated by MYCN through TFAP4 or commonly 
regulated by both transcription factors. Notably, TFAP4 
did not regulate any genes in an antagonistic direction to 
MYCN in this subset of genes, suggesting that these two 
transcription factors cooperatively regulate specific target 
genes that play critical roles in the development of the 
aggressive phenotype of neuroblastoma. This notion was 
supported by the observation that MYCN and TFAP4 were 
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able to bind to their respective binding sites closely located 
on the promoters of the two target genes, PRPS2 and 
SDC1 (CD138); while simultaneous depletion of MYCN 
and TFAP4 resulted in further reduction of promoter 
activity of both these genes. PRPS2, a key rate-limiting 
enzyme within the nucleotide biosynthesis pathway, has 
been previously reported to be a MYC target gene [16]. 
In cancer cells, PRPS2 has been reported to be involved 
in nucleotide metabolism in melanoma and lymphoma 
and hence is proposed to be a potential therapeutic target 
for MYC-overexpressing cancers [16, 17]. SDC1, a 
transmembrane (type I) heparan sulfate proteoglycan is 
involved in growth factor signalling, cell proliferation, 
migration and cell-matrix interactions via its receptor for 
extracellular matrix proteins [20]. Ishikawa et al, (2010) 
reported that suppression of SDC1 leads to more invasive 
and metastatic tumor cells [21]. The molecule can exist 
in either a membrane-bound or soluble form, and the 
Figure 4: TFAP4 gene expression is prognostic for poor outcome in primary neuroblastoma. Kaplan–Meier curves for 
event-free survival (EFS) and overall survival (OS) from (A) Oberthuer cohort (n = 649) and (B) COG cohort (n = 208), dichotomized 
around the upper decile. (c) TFAP4 expression levels were significantly higher in MYCN-amplified compared to non-MYCN-amplified 
tumors. 
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former cell-surface SDC1 has been shown to have roles in 
tumor formation and progression [22], while shed SDC1 
correlates with a more aggressive phenotype and may be a 
potential prognostic marker for a number of adult cancers 
including colorectal cancer, lung cancer and multiple 
myeloma [18].
SLC7A6, the only other gene found to be positively 
regulated by both MYCN and TFAP4, is a sodium 
dependent neutral amino acid transporter belonging to the 
L-type amino acid transporter (LAT) family, and increased 
expression of some LAT family members has been shown 
to be critical for control of protein translation in cancer 
via the mTORC1 pathway [23]. Our findings that high 
levels of expression of PRPS2, SDC1 and also SLC7A6 are 
associated with poor clinical outcome in neuroblastoma, 
and that PRPS2 and SDC1 are important in proliferation, 
suggest that these genes may facilitate tumor progression 
in MYC- and MYCN-driven cancers.
TFAP4 has been shown to repress or activate 
different target genes, and it is not able to form 
heterodimers with other helix-loop-helix transcription 
factors [5]. In our study, we found that TFAP4 was 
involved more often in repression (9.45%) than activation 
(3.06%) of MYCN target genes. Similarly, ChIP-
sequencing analysis in colorectal cancer cells showed 
that ChIP signals from TFAP4-repressed genes were 
more pronounced than those of TFAP4-activated genes 
[7]. These data suggest that TFAP4 has a major role in 
gene repression in tumors with deregulated MYC. One 
of the nine genes we confirmed to be repressed by both 
MYCN and TFAP4, CYLD, a deubiquitinating enzyme 
that negatively regulates NF-κB activation [24], is a 
well-established tumor suppressor gene, and loss of 
CYLD expression has been observed in various human 
cancer types [25]. Our findings that high CYLD levels 
are predictive for good prognosis in neuroblastoma 
(Supplementary Figure S4) are in agreement with a 
recent report showing that higher CYLD expression in 
neuroblastoma patient samples correlated with better 
survival and early tumor stages, and CYLD expression was 
significantly lower in MYCN-amplified tumors [26]. In 
addition to CYLD, knockdown of DENND5A in MDCKII 
cells was reported to lead to an increase in cell migration 
[27], while SSU72 was shown to be downregulated in the 
progression to hormone-refractory prostate cancer [28]. 
In gastric cancer cells, COPS8 has been reported to be 
part of G protein-coupled receptor pathway responsible for 
inhibiting the activation of NF-κB [29]. In contrast to these 
results however, overexpression of FMR1, which encodes 
fragile X mental retardation protein, has been associated 
with aggressiveness of breast cancer while its inhibition 
led to a reduction in invasiveness [30]. Interestingly, some 
of the highest levels of FMR1 are found in differentiated 
neurons and Gessert et al, [31] have shown that this 
RNA binding protein is necessary for proper neural crest 
development (the cell of origin of neuroblastoma) in 
Xenopus laevis. Thus, it remains to be established what 
role FMR1 has in neuroblastoma tumorigenesis. The 
remaining genes found to be negatively regulated by 
MYCN and TFAP4, appear to be largely uncharacterised 
in cancer and their functions in neuroblastoma require 
investigation.
In colorectal cancer, TFAP4 was found to be 
required for MYC-induced EMT, migration, and invasion 
providing strong evidence for this transcription factor 
being a new regulator of EMT contributing directly to 
colorectal cancer metastasis [7]. Although MYC can bind 
to the promoter of SNAIL, a transcription factor known to 
induce EMT [32], induction of SNAIL by MYC is largely 
mediated via upregulation of TFAP4 [7]. In addition, 
these authors found that SNAIL is also a target of TFAP4. 
Interestingly, in melanoma cells, SNAIL has been shown 
to inhibit expression of CYLD, which in turn leads to 
increased melanoma proliferation and invasion [33]. 
Figure 5: Confirmation of differentially expressed genes from microarray. Gene expression was measured by qPCR 48 h after 
depletion of MYCN (A) or TFAP4 (B) in BE(2)-C cells. Mean ± S.E. (four independent transfections with two siRNAs to either MYCN or 
TFAP4). *P < 0.05, **P < 0.01.
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Figure 6:  PrPS2 and Sdc1 are direct transcriptional targets of MYcn and tFAP4 in neuroblastoma. (A–d) Western 
blots of PRPS2 and SDC1 expression in BE(2)-C and SH-EP/S1 48 h after suppression of MYCN or TFAP4 or 72 h after suppression of 
MYCN expression in SH-EP/TET21/N cells (n ≥ 2). (e) Quantitative ChIP assays on BE(2)-C cells. Fold enrichment is relative to the 
preimmune serum. Mean ± S.E. (n = 5) in which each region was amplified by qPCR in triplicate. Bent arrow: transcriptional start site 
(TSS); Dist. (Distal region); grey arrow: TFAP4 binding site; black arrow: E-box (MYCN binding site); black boxes: amplicons indicated 
with a capital letter. The chromosome and coordinates (bp) are provided. (F) Luciferase activity was determined following transfection of 
reporter constructs into BE(2)-C transfected with TFAP4 and/or MYCN siRNA, or control siRNA. ***P < 0.001. 
Taken together with our study, TFAP4 appears to be 
initially upregulated by MYC or MYCN, after which it 
cooperatively regulates the same target genes to maximize 
rapid transcriptional activity in cancer cells. In this 
regard, a genome-wide analysis of TFAP4 DNA binding 
using ChIP-sequencing revealed a similar overall gene 
distribution pattern for TFAP4- and MYC-binding sites 
in colorectal cancer [7], suggesting that TFAP4 could be 
involved in regulation of a large number of genes targeted 
by MYC in this malignancy, and further supporting the 
concept of TFAP4 and MYC cooperatively regulating a 
number of genes in MYC-driven cancers. 
In MYC–induced EMT in colorectal cancer, TFAP4 
has been shown to regulate a number of EMT-associated 
genes such as CDH1, CDH2, VIM and SNAIL. TFAP4 
transcriptionally induces SNAIL, and both TFAP4 and 
SNAIL repress CDH1. In addition, TFAP4 protein is 
associated with Vimentin expression and inversely 
correlated with E-cadherin expression in seven colorectal 
cancer cell lines [7]. Consistent with this study, we 
found upregulation of SNAIL as well as downregulation 
of KRT8 by elevated expression of TFAP4 in SH-SY5Y 
cells (Supplementary Figure S5). However, CDH1 
was also upregulated in SH-SY5Y cells as well as in 
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SK-N-FI cells, which is not in agreement with the general 
finding that CDH1 is repressed in EMT. As an early 
event in EMT, cells commonly undergo a switch from 
E-cadherin to N-cadherin, and N-cadherin expression has 
been associated with increased motility and invasiveness 
[34]. In our study, CDH2 remained unchanged following 
overexpression of TFAP4. In addition, we observed 
no change in expression of TWIST, a well-established 
EMT-inducing gene that promotes tumor invasion and 
metastasis [35]. Furthermore, we saw reduced expression 
of ZEB1, another master EMT-inducing gene, which is 
generally activated in EMT [36]. Importantly, we found 
no change in gene expression of Vimentin, a hallmark in 
cells undergoing EMT (high Vimentin and low E-cadherin 
expression) [37]. A number of other genes involved in 
EMT in neuroblastoma, such as ACTN4, MYH9, ROCK1 
and TCF3 [38, 39], failed to show any significant changes 
in our studies. Finally, we did not observe obvious 
cell morphological changes 72 hours after transient 
overexpression of TFAP4.  
Collectively, the present data do not suggest TFAP4 
has a major role in the EMT phenotype of neuroblastoma. 
We showed TFAP4 promotes cell migration in 
neuroblastoma cell lines BE(2)-C, SH-SY5Y and SK-N-FI 
(Figure 3, Supplementary Figure S2A) and we believe this 
is, at least partly, achieved through activation of TFAP4 
target genes such as SDC1. However, since transient 
expression of TFAP4 caused upregulation of SNAIL and 
downregulation of KRT8 in SH-SY5Y cells, and a trend 
in reduction of CDH1 at 48 hours compared to 24 hours 
(still higher than control) in both SH-SY5Y and SK-N-
FI cells (Supplementary Figure S5), it could be possible 
that the effect of TFAP4 on EMT happens at much later 
timepoints, and this remains to be explored.    
MYC is a “master regulator” of two interrelated 
processes in transformed cells, cellular growth and 
metabolism, and remodelling of cancer metabolic 
pathways by MYC is vital for maintenance of a rapid 
cellular proliferation phenotype in MYC-transformed 
cells [40, 41]. To our knowledge, this is the first study 
to investigate the role of TFAP4 in MYCN-driven 
neuroblastoma. Our data support the existence of a 
regulatory circuit between MYCN and TFAP4, where 
TFAP4 is directly induced by MYCN, then cooperates 
with MYCN to regulate a subset of MYCN-target genes 
involved in cancer cell proliferation and metastasis, 
Figure 7: the role of PrPS2 and Sdc1 in neuroblastoma progression. (A–B) Suppression of PRPS2 or SDC1 resulted in 
reduction of colony forming ability in BE(2)-C cells. (c–d) SDC1 suppression significantly decreased migration, while PRPS2 suppression 
showed no significant effect. Mean ± SD (n = 3), **P < 0.01. 
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nucleotide and protein synthesis and growth. In particular, 
we have identified PRPS2 and SDC1 as genes that are 
positively regulated by both MYCN and TFAP4, and 
which represent novel candidate therapeutic targets for 
MYCN-driven neuroblastoma.
MAterIAlS And MethodS
Gene silencing, transfection, cellular assays
Human neuroblastoma cell lines BE(2)-C and SH-EP 
were obtained from the laboratory of Barbara Spengler 
[42]. Human SH-EP/TET21/N cells, derived from SH-EP 
neuroblastoma cells, express MYCN under the control 
of tetracycline (Tet-off) [43, 44]. SH-EP/S1 cells were 
derived from SH-EP cells by stable transfection with 
MYCN-expression vector. Neuroblastoma cell lines IMR-
32, SH-SY5Y, SK-N-FI and CHP-134 were obtained from 
American Type Culture Collection (Rockville, MD). Cell 
lines were systematically validated using short tandem 
repeat genetic profiling (CellBank Australia, Sydney) and 
mycoplasma tested. Cell lines were cultured in DMEM or 
RPMI containing 10% fetal calf serum (FCS).
Lipofectamine® RNAiMAX and Lipofectamine 
2000 (Invitrogen) were used to deliver siRNA (20–40 nM) 
or plasmids (5 µg AP4-FLAG (OriGene, MD), MYCN 
(#240081, Agilent Technologies) or empty vector). Qiagen 
siRNAs were: Control (#SI03650318); MYCN 
(#SI03078222,#SI03087518); TFAP4 (#SI00049322, 
#SI03057558); SDC1 (#SI00020601, #SI03072230), 
PRPS2 (#SI00042903, #SI03076997). SMARTpool human 
MYCN siRNA was from Dharmacon (#M-003913-01).
Colony forming assays were performed as described 
[45], with cells replated 48 h post-transfection and colonies 
of greater than 50 cells counted. For cell cycle analysis, 
cells at 48 h or 72 h post-transfection were fixed with 
ice-cold 70% ethanol for 1 h before incubation at 37°C 
(30 min) in PBS with added propidium iodide (50 µg/mL) 
and RNase A (2 µg/mL). Stained cells were analyzed for 
DNA content on a FACSCalibur flow cytometer using 
CELLQuest analysis software (BD Biosciences).
Wound closure assays and transwell migration 
assays were performed as published [46, 47].
Western blot
Western blots were performed according to standard 
procedures [48] using 25 µg of whole-cell extract. 
Syndecan-1 (SDC1) protein samples were prepared 
by scraping cells in lysis buffer. Antibodies used were 
MYCN (B8.4B, #sc-53993, 1:2000, or C-19, #sc-791, 
1:500, Santa Cruz) [49], p27kip1 (BD Biosciences #610241, 
1:2000) [50], TFAP4 (Abcam #ab58288, 1:2000), FLAG 
(anti-Flag-M2, Agilent Technologies #200471, 1:2000), 
SDC1 (D4Y7H, Cell Signaling #12922S, 1:1000), PRPS2 
(Abnova #H00005634-A01, 1:1000) [16],  GAPDH (G-
9, Santa Cruz #sc-365062, 1:3000), Actin (Sigma-Aldrich 
#A2066, 1:5000).
Microarray analysis
Neuroblastoma BE(2)-C cells were transfected with 
scrambled control siRNA or two independent siRNAs for 
MYCN and TFAP4. 30 h post-transfection, total RNA was 
extracted with RNeasy Plus Mini kit (Qiagen). Differential 
gene expression was examined with GeneChip® Human 
Genome U133 Plus 2.0 Array (Affymetrix). Results were 
loaded into R package and analysed with BioConductor 
software.
real-time quantitative Pcr and taqman low 
density Array (tldA) analyses
RNA was extracted using an RNA Extraction kit 
(Qiagen) and reverse transcribed with MMLV reverse 
transcriptase (Life Technologies). Gene expression 
was determined by quantitative PCR (qPCR) using 
the ABI7900HT sequence detection systems (Applied 
Biosystems, ThermoFisher Scientific) for TaqMan® 
Assays, or CFX96 real-time PCR detection system (Bio-
Rad) for SYBR® Green assays. The ΔΔCt method was 
used to compare expression of target genes normalized to 
the expression of reference genes (GUSB, HPRT or actin).
Gene expression analyses  were performed on 
208 primary neuroblastoma tumors (COG cohort) from 
patients enrolled in Children’s Oncology Group (COG) 
Neuroblastoma Biology Study 9047 [46]. qPCR with 
TaqMan® gene expression assays were conducted on a 
TLDA platform using a 7900HT Fast Real-Time PCR system 
(Applied Biosystems, ThermoFisher Scientific). TLDA 
cards were loaded with 125ng cDNA (RNA equivalent) per 
loading port. Gene expression levels were determined using 
the ∆∆Ct method relative to a calibrator [48]. Expression 
values were calculated as the geometric mean of values 
normalized to control genes HPRT, GUSB and PPIA. 
TaqMan® Assays for qPCR were: TFAP4 
(Hs00231478_m1), MYCN (Hs00232074_m1); SDC1 
(Hs00896423_m1); PRPS2 (Hs00267624_m1); 
SLC7A6 (Hs00938056_m1); CYLD (Hs00211000_m1); 
MFSD6 (Hs00214462_m1); FMR1 (Hs00924547_
m1); C SGALNACT2 (Hs00603821_m1); DENND5B 
(Hs00958915_m1); SSU72 (Hs00982637_m1); LCORL 
(Hs00766084_m1); FAM73A (Hs01594834_m1), C19orf12 
(Hs01107514_m1); OIP5-AS1 (Hs01587688_g1); COPS8 
(Hs00991301_g1); HPRT (Hs02800695_m1); GUSB 
(Hs00939627_m1); PPIA (Hs99999904_m1). qPCR assays 
for TFAP4 expression using SYBR® Green were performed 
using published primers [6]. qPCR assays for EMT-
associated genes using SYBR® Green were performed 
using primers listed in Supplementary Table S2.
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chromatin immunoprecipitation (chIP) and 
luciferase assays
ChIP assays were performed as described [43] 
on neuroblastoma BE(2)-C and SH-EP/TET21/N cells. 
Antibodies employed for ChIP assays were: MYCN 
(#sc-53993, Santa Cruz Biotechnology) [49], MAX 
(#sc-197, Santa Cruz) [51] and TFAP4 (#HPA001912, 
Sigma-Aldrich) [7]. Primers for quantitative ChIP are 
listed in Supplementary Table S1. Luciferase assays were 
performed as published [43]. 
Statistical analysis
For molecular and cellular assays, differences 
between two groups were analyzed by two-tailed Student’s 
t-test. P < 0.05 was considered statistically significant. 
Associations between expression levels of a given gene 
and clinical characteristics of patients were analyzed using 
Fisher’s exact test.  Univariate and multivariate analyses 
for event-free survival (EFS) and overall survival (OS) 
were performed using SPSS version 22 (IBM, Mainz, 
Germany) as described [46]. For each cutoff point, a 
Cox model produced a P-value and hazard ratio and 
the optimal expression cutoff point was determined as 
described previously [52]. Pearson correlation test was 
performed to analyze the correlation between expression 
of TFAP4 and MYCN.
Abbreviations
ChIP, chromatin immunoprecipitation; COG, 
Children’s Oncology Group; CYLD, cylindromatosis; 
EFS, event-free survival; EMT, epithelial-mesenchymal 
transition; OS, overall survival; PRPS2, phosphoribosyl-
pyrophosphate synthetase 2; SDC1, syndecan-1; TFAP4, 
transcription factor activating enhancer binding protein-4.
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